|
 |
| |
| Home > People |
| |
|
| |
| |
|
|
| |
|
|
 |
|
| |
| Davies began his career in Anatomy and Dentistry and practiced Oral Maxillofacial Surgery before starting his research career. He currently holds a Professorship at the University of Toronto. As the technical founder of Tissue Regeneration Therapeutics Inc., Davies’ pioneering research gave rise to all the proprietary technology at TRT. His creative vision and expertise drives the design and implementation of the Research & Development program at TRT. |
| |
| He is internationally recognized as a leader in the bone biomaterials and bone engineering fields, and was the 2000 recipient of the Clemson Award for Basic Science for his seminal contributions to this field. It was his group that discovered the human umbilical cord perivascular cells (HUCPVCs). Furthermore, he has developed several novel bone-substitute materials including a thin film ceramic osteoclast resorption substrate, which was used by the Canadian Space Agency as a platform technology for several bone cell experiments that flew on the STS 95 Shuttle Mission. |
|
| |
|
|
| |
|
|
 |
|
| |
| In July 2006, Turner joined the TRT team as the full-time Chief Executive Officer (CEO), bringing with him a zest for both business and science. His unique blend of enthusiasm, energy and professionalism launched TRT into a new phase of business development. Within a year, Turner redeveloped the business strategy of TRT and secured private and corporate investments worth millions of dollars in the company. |
| |
| Prior to TRT, Turner founded Nexia
Biotechnologies Inc. (TSX: NXB) in 1993, a
venture capital start-up with $25 M, then
completed a $42 M IPO in December of 2000.
Turner served as President and CEO until May
2003 when Nexia sold the Protexia®
product line and the company’s manufacturing
infrastructure to a US biodefense company.
Prior to Nexia, Turner held tenure at McGill
University (Associate Professor, Molecular
Genetics). |
|
| |
|
|
| |
|
|
 |
|
| |
| Hosseini studied biotechnology at the TU Braunschweig, where he obtained his Master of Science degree in 1995. He completed his PhD with Davies at the University in Toronto. Hosseini is an inventor of the HUCPVC technology and conducted research in the field of bioreactor-based tissue engineering at the University in Ulm, Germany and at the National Institute for Biotechnology in Braunschweig. |
| |
| In 2000, Hosseini joined Roland Berger – Strategy Consultants in Munich, New York and Berlin where he is a Senior Project Manager in the Competence Center for Pharmaceuticals and Healthcare. As Chief Business Officer, Hosseini brings experience in the fields of pharmaceuticals manufacturing, regulatory affairs, marketing and sales, as well as licensing and strategic partnering. |
|
| |
|
|
| |
|
|
 |
|
| |
| With meticulous skill as a lawyer and chartered accountant Rath brings 20 years of corporate experience to TRT. He joined the company in June of 2007. His duties include managing finance, taxation, treasury and accounting functions. Rath oversees internal controls on an administrative and departmental level to ensure efficient corporate management. |
| |
| His career path has been extensive and significant as Vice-President Finance & Administration and Corporate Secretary at Nexia Biotechnologies Inc.; Taxation Manager at Abbott Laboratories Ltd.; and Tax Manager at Ernst & Young Chartered Accountants. In 1986, Rath earned Admission to the Canadian Institute of Chartered Accountants. |
|
| |
|
|
| |
|
|
 |
|
| |
| In September 2006, Ennis became the full-time manager of our mesenchymal stem cell program. Ennis manages all aspects of the HUCPVC development program including: applied Research & Development, stem cell collection and preservation during manufacturing scale-up, as well as the Canadian clinical development program. She holds a Masters of Applied Science from the Institute of Biomaterials and Biomedical Engineering, University of Toronto. She is an inventor of two patents covering cryogenic preservation, HUCPVCs and their clinical indication for the treatment of autoimmune and inflammatory diseases. |
|
| |
|
|
| |
|
|
 |
|
| |
| In December 2006, Guan became
the full-time manager of the TRT biomaterials
department. He is an original inventor of
OsteoScaf™ and continues
to enhance the biological evolution of the
material in vivo. He graduated from
the University of Toronto with a Masters of
Applied Science from the Institute of Biomaterials
and Biomedical Engineering. Guan is a key
consultant in the design of the OsteoScaf™
manufacturing facility in Texas, USA and in
the mass-production and characterization of
biomaterials. |
|
| |
|
|
| |
|
|
 |
|
| |
| With her specialization in umbilical cord dissection and extraction of HUCPVCs Cheng is responsible for the transfer of HUCPVC technology and training of technical personnel from our international licensees. She is also responsible for the Quality Assurance and Quality Control functions including the creation and documentation of all Standard Operating Procedures for the processing and cryogenic storage of HUCPVCs. |
|
| |
|
|
| |
|
|
 |
|
| |
| As a certified journalist with
promotional and public relations experience,
Sola manages TRT communications. With her
keen ability to multitask, she handles all
executive administrative duties and liaises
between internal departments, partner companies,
and investors. Sola joined Davies’ laboratory
at the University of Toronto as his personal
assistant following a successful career in
the film industry. She now brings her experience,
enthusiasm, and flare to the forefront of
TRT. |
|
| |
|
|
| |
|
|
|
| |
|
|
|
